Investor Presentation • Mar 21, 2017
Investor Presentation
Open in ViewerOpens in native device viewer
STAR CONFERENCE, Milan 21/22 March, 2017
Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-lookingstatements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Hi-Tech industrial group active in opto-electronics with proprietary technologies and knowhow developed over 35 years
More than 20 companies active worldwide on several markets and application segments. Listed on the Milan Stock Exchange, Star segment
Among the leaders in the global market
Progressively widening its worldwide presence registered continuous growth over the years
Worldwide distribution network
1,093 employees worldwide, more than 40,000 laser sources sold
13% Revenue CAGR 2011 – 2016
40% EBIT CAGR 2011 – 2016
FY 2016 Consolidated Revenue at €253m, up 16% YoY
El.En. designs, manufactures ad sells worldwide: MEDICAL laser devices – INDUSTRIAL laser solutions – laser systems for CONSERVATION of the cultural heritage
Combine High tech laser source development with flexible production facilities focusing on applications
Technological and clinical innovation improving performances and broadening the application scope of our laser systems
-New applications
-Improved efficacy and effectiveness of current applications
Leverage worldwide distribution with multi brand approach
Source: World Health Organization, ASAPS
Key growth drivers:
| k S M t t a r e e g m e n |
2 0 1 4 |
2 0 9 1 |
C G % A R |
|---|---|---|---|
| 2 0 1 4 2 0 1 9 - |
|||
| l S i u r g c a |
8 1 3 |
1 2 1 9 |
8 4 % , |
| C i t o s m e c |
1 0 2 4 |
2 0 9 7 |
1 % 5 4 , |
| l D t e n a |
2 4 4 |
6 2 3 |
2 0 % 7 , |
| i V t e e r n a r y |
1 1 5 |
2 4 7 |
6 % 1 5 , |
| l T t o a |
2 9 1 5 |
8 4 1 5 |
3 8 % 1 , |
Source: BCC research
DISCOVERY PICO
MOTUS AX
| l V B y a u e |
( ) C A G % R |
||||
|---|---|---|---|---|---|
| 2 0 1 6 |
2 0 2 0 |
2 0 1 3 2 0 1 6 - |
2 0 1 6 2 0 2 0 - |
||
| C i t t u n g |
3 0 1 4 |
3 9 6 5 |
7 8 , |
7 1 , |
|
| l d d i i W B e n g a n r a z n g |
1 6 0 5 |
2 2 3 1 |
8 7 , |
8 6 , |
|
| f d h S O t t t t r a c e r e a m e n a n e r u |
6 3 |
8 6 |
8 3 , |
8 1 , |
|
| l T t o a |
6 8 2 4 |
6 2 8 2 |
8 1 , |
6 7 , |
Source: Optech Consulting
RF177
| l l i i E M u r o o n |
/ / 3 1 1 2 2 0 1 5 |
% | / / 3 1 1 2 2 0 1 6 |
% | V % a r. |
|---|---|---|---|---|---|
| d d i t u n a u e |
|||||
| R e v e n u e s |
2 1 6 0 7 7 |
1 0 0, 0 % |
2 2 6 6 5 4 |
1 0 0, 0 % |
1 6, 1 % |
| G i r o s s m a r g n |
9 6 3 1 8 |
4 4, 2 % |
1 1 0 5 3 3 |
4 3, 8 % |
1 4, 8 % |
| E B I T D A |
2 6 6 6 5 |
8 % 1 1, |
3 2 3 8 8 |
2, 8 % 1 |
2 6, 2 % |
| E B I T |
2 1. 4 9 9 |
% 9, 9 |
2 7 5 9 4 |
% 1 0, 9 |
% 2 8, 4 |
| I P t r e a x n c o m e |
2 3 1 1 3 |
1 0, 6 % |
2 2 1 5 7 |
2 0, 9 % |
1 2 8, 1 % |
| N i t e n c o m e |
1 4 3 7 1 |
% 6, 6 |
4 0 4 0 8 |
% 1 6, 0 |
% 1 8 1, 2 |
| h N I t e n c o m e p e r s a r e |
0, 7 4 |
2, 0 9 |
| l l E M i i u r o o n |
/ / 3 1 1 2 2 0 1 5 |
/ / 3 1 1 2 2 0 1 6 |
V % a r. |
|---|---|---|---|
| d d i t u n a u e |
|||
| l T t t t o a n o n c r r e n a s s e s u |
9 6 6 7 7 |
6 3 4 7 7 |
3 3, 8 % - |
| k l N W i C i t t e o r n g a p a |
5 9 8 6 1 |
5 4 1 6 0 |
9, 5 % - |
| f l i i i i N t t e n a n c a p o s o n |
2 9 8 1 5 |
8 2 7 8 4 |
% 1 7 7, 7 |
| l b l L i i i i t t o n g e r m a e s |
7 9 0 4 |
8 9 8 2 |
1 3, 6 % |
| i N E t t e q u y |
1 7 9 5 3 9 |
1 9 2 6 9 9 |
% 7, 3 |
| l l d i N t t e c a p a e m p o e y |
1 9 2 4 7 4 |
1 0 9 9 1 5 |
2 6, 6 % - |
| k l l i C i N W t t e o r n g a p a o n s a e s |
2 8 % |
2 1 % |
|
| R O C E |
1 4 % |
2 5 % |
|
| / ( l l d ) i E B I T N t t e c a p a e m p o y e |
|||
| C a p e x |
8 2 3 4 |
1 1. 4 4 1 |
in Euro million
| k h l 's h d i S E t t o c o e r q u y p e r s a r e |
9 |
|---|---|
| k l d i P B V A |
8 |
| / j. r c e o o a u e |
2, |
| / ( ) E V E B I T 8 5 % E B I T |
1 7, 8 |
| / ( ) l l E V S 8 5 % S a e s a e s |
1, 9 |
| l. k E E M C t n. a r e a p. |
@ 5 1 0, 4 |
€ 2 6, 4 5 |
|---|---|---|
| f l i i i i N t t e n a n c a p o s o n |
@ 8 2, 8 |
/ / 3 1 1 2 2 0 1 6 |
| / l l i i i F t t t n a n c a n v e s m e n s m e r m |
0, 9 @ 1 |
/ / 3 2 2 0 6 1 1 1 |
| i l E V t n e r p r s e a e u |
4 1 6, 8 |
| Dec. 31st, 2016 Medical/Aesthetic |
Price | Revenue | Var.% Revenue |
EBIT | EBIT % | MK.Cap. | EV | EV/Sales | EV/EBIT | P/E | P/Book Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Syneron | \$10,40 | \$298.102 | 7% | \$3.228 | 1% | \$357.560 | \$271.139 | 0,9 | 84,0 | 1997,5 | 1,7 |
| Zeltiq | \$55,64 | \$354.201 | 39% | \$13.224 | 4% | \$2.240.000 | \$2.181.621 | 6,2 | 165,0 | 3227,7 | 16,3 |
| Cutera | \$20,85 | \$118.056 | 25% | \$2.397 | 2% | \$295.480 | \$241.406 | 2,0 | 100,7 | 114,7 | 4,8 |
| Biolase | \$1,20 | \$51.810 | 7% | \$(14.962) | -29% | \$86.020 | \$76.845 | 1,5 | n.a. | n.a. | 3,9 |
| Cynosure | \$65,97 | \$433.532 | 28% | \$27.340 | 6% | \$1.610.000 | \$1.391.790 | 3,2 | 50,9 | 113,4 | 3,5 |
| Industrial | |||||||||||
| IPG Photonics Co. | \$120,29 | \$1.006.173 | 12% | \$364.313 | 36% | \$6.440.000 | \$5.612.554 | 5,6 | 15,4 | 24,7 | 4,1 |
| Prima Industrie | € 21,60 |
393.886 € |
8% | € 18.528 |
5% | € 226.440 |
\$310.655 | 0,8 | 16,8 | 22,3 | 1,6 |
| E.I.En. (1) | € 26,45 | 252.646 € |
16% | € 27.594 |
11% | € 510.418 |
\$416.753 | 1,9 | 17,8 | 12,6 | 2,8 |
| $28,5$ (*) |
(1) EV and multiplies as for previous slide
(*) w/o one time income
Cohrent (COHR) acquired Rofin-Sinar (RSTI) in 2016 (equity value \$942m)
Hologic acquired Cynosure (CYNO) , closing pending (equity value \$1.65 bn)
Allergan bought Zeltiq (ZLTQ), closing pending (equity value \$2.48bn)
Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]
Financial Communication, IR and Press Office Bianca FERSINI MASTELLONI [email protected]@polytemshir.it ; [email protected] Tel. +39 06-69923324
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.